GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign.

M. tuberculosis (strain H37Rv):0.38 μM (MIC)

GSK2200150A 是一种针对结核分枝杆菌（Mycobacterium tuberculosis）的新型抗菌药物。含有螺旋环核心的 GSK2200150A 对致病性的 M.tuberculosis 株（H37Rv）显示出显著的活性，最小抑菌浓度（MIC）为 0.38 μM [1]。

GSK2200150A is tested for activity at either single concentration (100 μM) or serially diluted in 10 μL of purified H2O in triplicate in 96 well microtiter plates. M. tuberculosis H37Rv is grown in complete Middlebrook 7H9 media containing albumin, dextrose and catalase (ADC), 20% Tween 80 and 50% glycerol. A bacterial suspension (90 μL) at OD600 nm of 0.001 is added to the wells and incubated for 7 days. Resazurin (10 μL; 0.05%(w/v)) is then added, incubated for 24 h at 37°C, and fluorescence measured at 590 nm using a FLUOstar Omega microplate reader. After subtraction of background fluorescence from all wells, the percentage mycobacterial survival is determined by comparing the fluorescence of wells containing compounds compared to control wells not treated with compound[1].